Scroll Back to Top
Accessibility
Accessibility
<span>Guangyu Gu, MD</span>
Guangyu Gu, MD
Director, Cytogenetics and Molecular Oncology
<span>Michael Cascio, MD</span>
Michael Cascio, MD
Anatomic Pathology, Clinical Pathology and Hematology
<span>Stephanie J. McAlhany, MD, PhD</span>
Stephanie J. McAlhany, MD, PhD
Hematopathologist, Medical Director
August 1, 2025

Calu-6 Human Non-Small Cell Lung Adenocarcinoma Model

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases.¹ Among its subtypes, adenocarcinoma is the most prevalent, often diagnosed at advanced stages due to its asymptomatic progression. The complexity of lung cancer, characterized by diverse histological subtypes and genetic mutations, presents significant challenges for effective therapeutic intervention and highlights the urgent need for robust preclinical models to unravel disease mechanisms and develop novel, more effective treatments. The Calu-6 cell line has emerged as a widely studied and well-characterized model in lung cancer research.²
Read more »

Labcorp Perspectives Oncology (Episode 6): Empowering breast cancer patients: Biomarker breakthroughs and self-advocacy

When Suzanne Garner was diagnosed with breast cancer at age 40, she wasn’t a medical expert, but she quickly became one of her own best advocates. On the latest episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs  talks with Suzanne, now Senior Director of Strategic Partnerships at Outcomes4Me, about her transformation from newly diagnosed patient to digital-health leader.

Read more »

Executive Q&A - Empowering Diagnostic Clarity in Hematologic Malignancies

 

Each year, NGS testing becomes increasingly important for identifying subtypes and treatment options in hematologic malignancies.

In this Executive Q&A video, medical director of Labcorp's Brentwood, Tennessee Stephanie McAlhany, discusses the lab's hematology testing, and about the support they offer in choosing tests and interpreting results.

 

Read more »

Molecular Tumor Board: 71-year-old male with gastrointestinal stromal tumor and KIT A502_Y503dup

In this recent Molecular Tumor Board, our Medical Affairs team reviewed a case of gastrointestinal stromal tumor (GIST) with a confirmed KIT mutation, highlighting how NGS-based Comprehensive Genomic Profiling (CGP) informs treatment. The discussion explored the biology of the kinase family and how molecular testing can differentiate alterations that may be sensitive or resistant to specific kinase inhibitors. This case underscores the power of precision medicine in guiding targeted therapy and improving outcomes in GIST.

Read more »
Subscribe to